Key result
HSCT peri-transplant therapy linked to worsening LV function, driven by age, cyclophosphamide, and prior anthracycline dose.
Why the study?
Does hematopoietic stem cell transplantation and associated peri-transplant therapy cause early cardiotoxic effects on left ventricular function in patients with hematologic malignancies?
Observational (n=47)
Does hematopoietic stem cell transplantation and associated peri-transplant therapy cause early cardiotoxic effects on left ventricular function in patients with hematologic malignancies?
Peri-transplant therapy during HSCT is associated with early cardiotoxic effects on both systolic and diastolic left ventricular function, with prior anthracycline exposure being a key risk factor for systolic dysfunction.
May warrant closer LV monitoring in older HSCT patients given cyclophosphamide; leaves open whether modifying these factors improves cardiac outcomes.
The purpose was to evaluate the early cardiotoxic effects of the treatment in the course of hematopoietic stem cell transplantation (HSCT) in patients with hematologic malignancies. The studies were conducted on 47 patients qualified for the HSCT. Echocardiography was carried out prior to the HSCT and after the HSCT. It was shown that higher age, administration of cyclophosphamide and higher glucose concentrations represented independent risk factors for the worsening of left ventricular diastolic function. Higher cumulative dose of anthracyclines in the previous cytostatic treatment, higher age and administration of cyclophosphamide represented independent risk factors for worsening of left ventricular systolic function. Peri-transplant therapy in the course of HSCT in patients with hematologic malignancies gives the negative effect on the diastolic and systolic left ventricular function, however, previous treatment is of importance, as higher cumulative dose of anthracyclines represents an independent risk factor for the worsening of left ventricular systolic function.
No takes yet. Share an insight, caveat, or question.
Poręba et al. (2016) conducted an observational in Hematologic malignancies (n=47). Hematopoietic stem cell transplantation (HSCT) and peri-transplant therapy was evaluated on Worsening of left ventricular diastolic and systolic function. In 47 patients with hematologic malignancies, peri-transplant therapy during HSCT negatively affected left ventricular function, driven by age, cyclophosphamide, and prior anthracycline dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: